Understanding the drivers of market concentration in the generic pharmaceutical industry is essential to guaranteeing the availability of low-cost generics. In this paper, we develop a structural model to capture the multiple determinants governing manufacturers' entry decisions; in particular,...

Using a multi-tier mapping of supply chain relationships constructed from granular global, firm-to-firm supplier--customer linkages data, we quantify the degree of financial risk propagation from the supply network beyond firms' direct supply chain connections and isolate structural network...

Close to 90% of drugs consumed in the US are generics, representing around 30% of the overall drug expenditure. Generic drugs have saved the healthcare system over 2.4 trillion dollars over the past decade. Such cost-saving benefit, however, can only be realized when the drug's effectiveness is...